Donate

Grifols announced that it will donate up to 20 million units of coagulation therapies in each of the next three (3) years to the World Federation of Hemophilia (WFH). Grifols has been a proud supporter of the WFH and its noble efforts for nearly a decade 鈥 and this unprecedented product donation represents its largest commitment to date. According to the WFH, this donation of blood clotting factor products will secure an average of 40,000 doses to treat approximately 10,000 patients in developing countries worldwide through 2017, where access to adequate treatment is often lacking or absent.

Grifols produces plasma-derived medicines to treat rare, genetic diseases such as hemophilia, and also develops solutions for the diagnoses of bleeding disorders. The donated therapies will be delivered from Grifols鈥 manufacturing facilities in California and North Carolina to a WFH-USA location, where it will then be distributed internationally by the WFH to patients in need. Grifols plans to increase its production volumes of varying vial sizes and concentrations in order to specifically meet its donation commitment to the WFH, with the first shipment planned for Q4 2014.

“World Hemophilia Day represents ideal timing for Grifols to reaffirm our long-standing commitment to bleeding disorders and the hemophilia community鈥, said Christopher Healey, Vice President of Public Affairs for the company. “In addition to obtaining treatments for hemophilia patients, the WFH does a tremendous job of raising awareness about bleeding disorders and advocating for patients. We are thrilled to be prominently partnered with them in their humanitarian efforts鈥.

An estimated 400,000 people around the world have hemophilia, yet only 25% receive adequate treatment. Grifols鈥 donation supports the second decade of WFH鈥檚 Global Alliance for Progress (GAP) program aimed at increasing the number of patients diagnosed and treated for bleeding disorders, particularly in the world鈥檚 most impoverished countries.

鈥淭his generous multi-year commitment from Grifols is perfectly aligned with the WFH philosophy of providing sustainable, predictable care in developing countries鈥, said Alain Weill, President, World Federation of Hemophilia.

锟糎emophilia is a hereditary bleeding disorder that prevents blood from clotting properly due to lack of a protein (clotting factor) that controls bleeding. Bleeding into joints and muscles can cause stiffness, pain, severe joint damage, disability, and sometimes death. Patients with more severe hemophilia require larger and more frequent doses of blood clotting factors.

For more information about the WFH, hemophilia and other bleeding disorders go to:聽http://www.wfh.org/

About Grifols

Grifols is a global healthcare company with a 70-year legacy of improving people鈥檚 health and well being through the development of life-saving plasma medicines, hospital pharmacy products and diagnostic technology for clinical use.

The company is present in more than 100 countries worldwide and its headquarters are located in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donation centers in the U.S., and a leading producer of plasma-derived biological medicines. The company provides a comprehensive range of solutions for in vitro diagnostics for clinical laboratories, blood banks and blood transfusion services, and it is a point of reference in the field of transfusion medicine.

In 2013, sales exceeded 2,740 million euros with a headcount of 13,200 employees. Annually, Grifols allocates approximately 5% of income to R&D; this investment is evidence of its commitment to scientific progress.

Media Inquiries

Grifols PR Agency:聽Raquel Lumbreras,聽raquel_lumbreras@duomocomunicacion.com

Borja Go虂mez ,聽borja_gomez@duomocomunicacion.com

Facebook Comments


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.